Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.
J Clin Exp Hepatol
; 9(3): 283-293, 2019.
Article
en En
| MEDLINE
| ID: mdl-31360020
Myanmar; direct-acting antiviral; direct-acting antivirals, DAAs; generic; hemoglobin, Hgb; hepatitis B virus, HBV; hepatitis C; hepatitis C virus, HCV; hepatocellular carcinoma, HCC; human immunodeficiency virus, HIV; ledipasvir, LDV; line probe assay, LiPA; pan-genotypic; pegylated interferon, PEG-IFN; ribavirin, RBV; sofosbuvir/velpatasvir; sofosbuvir/velpatasvir, SOF/VEL; sustained viral response, SVR
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
J Clin Exp Hepatol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Myanmar